Boss Energy

Boss Energy is under Algo Engine sell conditions.

Shares of Boss Energy tanked 25 per cent and hit a four-year low after withdrawing a feasibility study for its Honeymoon project in South Australia.

The uranium miner confirmed 2025-26 financial year production and cost guidance, but flagged a 15 per cent increase in all-in sustaining costs for the following year.

The stock has cratered 52 per cent this year.

Xero

16/12 update: XRO is trading at $110, and we’re monitoring price action for increased buying interest and a close above the 10-day average.

Xero Add to your watchlist.

1H26: Overall, a weaker result vs market expectations despite EBITDA a slight beat. EBITDA-capex cash flow came in -6% below consensus. Whilst operating costs have seen good control, capex spend is trending up due to investments in new AI capabilities.

Look for buying interest to rebuild, and we’ll revisit the entry point once the price action is above the 10-day average.

4D Medical

Update 12/12: 4DMedical jumped 10.8 per cent after securing $30.2 million in funding via an underwriting agreement with Bell Potter Securities to ensure the exercise of all its listed options.

4D Medical confirmed that the University of Miami has commenced clinical use of its CT:VQ respiratory imaging technology, becoming the second US academic medical centre after Stanford to adopt the system.

10/12 update: Hold and wait for a break below the 10-day average to close the trade.

24/11 update: Buy with a stop loss at $1.40

17/11 update:

4Dmedical

Add to your watchlist and wait for a close above the 10-day average.